Mark Andrew Schroeder MD

Hematologic Oncology

Assistant Professor of Medicine

4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSt. Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902

Dr. Schroeder is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schroeder's full profile Already have an account?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
University of Cincinnati College of MedicineClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2018 - 2029
MO State Medical License 2006 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2015-2017
CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2015-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2015-2017

Clinical Trials

Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant Start of enrollment: 2015 Mar 25
COMPLETED
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
TERMINATED
PHASE1

Publications & Presentations

PubMed

Pulmonary Light Chain Deposition Disease in a Patient With Chronic Lymphocytic Leukemia.
Taylor L Wilson, Jacqueline E Payton, Mark A Schroeder, Lisa D Yuen
International Journal of Surgical Pathology. 2026-08-18
Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.
Zachariah DeFilipp, Amin Alousi, John E Levine, Shernan G Holtan, Sameem Abedin
Transplantation and Cellular Therapy. 2026-05-20
Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.
William A Wood, Shaji K Kumar, Emily A Semmel, Shandra James, Mark A Schroeder
Blood Advances. 2026-05-12

Journal Articles

Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

SYNTHETIC BIOLOGICS, INC. MANAGEMENT's DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (Form 10-Q)August 11th, 2022
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraftOctober 23rd, 2020
St. Louis: One of the Fastest-Growing Life Sciences MarketsMarch 27th, 2019